Frontiers in Medicine (Nov 2023)

Microbacterium spp. peritonitis in patients undergoing peritoneal dialysis: a single-center experience and literature review

  • Xiao Yu,
  • Xiao Yu,
  • Zhao Li,
  • Xinbo Yang,
  • Xiaopei Wang,
  • Di Nan,
  • Wanhong Lu,
  • Jing Lv,
  • Ying Ma

DOI
https://doi.org/10.3389/fmed.2023.1297296
Journal volume & issue
Vol. 10

Abstract

Read online

IntroductionPeritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is very rare, with only 9 cases reported to date. In this study, we report the treatment experiences of 7 patients at our peritoneal dialysis center.MethodsWe retrospectively collected clinical characteristics and antibiotic management of all 7 episodes of PDRP caused by Microbacterium spp. in 7 patients from at our center over 4 years, and reviewed the documented Microbacterium spp. PDRP in the literature.ResultsEmpiric antibiotic therapy was initiated as soon as possible, and consisted of intraperitoneal (IP) gentamicin in combination with vancomycin. After up to 5 days, gentamicin was changed to meropenem if the treatment was not effective. The intended course of antibiotic treatment was 21-day. Totally, 6 episodes were cured (85.7%), which was higher than reported.ConclusionThe 21-day antibiotic therapy program by combining vancomycin and meropenem may benefit the management of Microbacterium spp. PDRP.

Keywords